8NN logo

Thor Medical ASADB:8NN Stock Report

Market Cap €145.7m
Share Price
n/a
1Y89.8%
7D2.6%
1D2.1%
Portfolio Value
​
View

Thor Medical ASA

DB:8NN Stock Report

Market Cap: €145.7m

Thor Medical (8NN) Stock Overview

Produces and supplies alpha-particle emitters for cancer therapy in Norway. More details

8NN fundamental analysis
Snowflake Score
Valuation0/6
Future Growth2/6
Past Performance0/6
Financial Health5/6
Dividends0/6

Rewards

Revenue is forecast to grow 28.52% per year

Risk Analysis

Makes less than USD$1m in revenue (NOK839K)

Currently unprofitable and not forecast to become profitable over the next 3 years


8NN Community Fair Values

Create Narrative

See what others think this stock is worth. Follow their fair value or set your own to get alerts.

NEW480,107 members

Join community and earn perks

Gain real feedbackFrom our editorial team, personally. Not silence.
Grow your followingReal investors. The kind who actually invest, not scroll past.
Unlock free accessFree premium subscription for consistent and quality authors.
Learn moreCreate Narrative
BL
BlackGoat
IN
Investingwilly
RO
RockeTeller
DA
davidlsander
480,107 investors already sharing narratives
View all narratives

Thor Medical ASA Competitors

Price History & Performance

Summary of share price highs, lows and changes for Thor Medical
Historical stock prices
Current Share PriceNOK 0.40
52 Week HighNOK 0.51
52 Week LowNOK 0.19
Beta-0.27
1 Month Change8.03%
3 Month Change-9.15%
1 Year Change95.09%
3 Year Change150.00%
5 Year Changen/a
Change since IPO135.19%

Recent News & Updates

Recent updates

Shareholder Returns

8NNDE BiotechsDE Market
7D3.7%-0.1%0.1%
1Y95.1%11.4%-0.5%

Return vs Industry: 8NN exceeded the German Biotechs industry which returned 13.3% over the past year.

Return vs Market: 8NN exceeded the German Market which returned 0.3% over the past year.

Price Volatility

Is 8NN's price volatile compared to industry and market?
8NN volatility
8NN Average Weekly Movement7.3%
Biotechs Industry Average Movement7.7%
Market Average Movement5.3%
10% most volatile stocks in DE Market12.7%
10% least volatile stocks in DE Market2.7%

Stable Share Price: 8NN has not had significant price volatility in the past 3 months compared to the German market.

Volatility Over Time: 8NN's weekly volatility (7%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
200918Jasper Kurthwww.thormedical.no

Thor Medical ASA produces and supplies alpha-particle emitters for cancer therapy in Norway. It offers thorium-228, as well as radium-224 and lead-212 to radiopharmaceutical customers. The company was incorporated in 2009 and is headquartered in Oslo, Norway.

Thor Medical ASA Fundamentals Summary

How do Thor Medical's earnings and revenue compare to its market cap?
8NN fundamental statistics
Market cap€145.74m
Earnings (TTM)-€5.30m
Revenue (TTM)€76.67k
1,901x
P/S Ratio
-27.5x
P/E Ratio

Is 8NN overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
8NN income statement (TTM)
RevenueNOK 839.00k
Cost of RevenueNOK 0
Gross ProfitNOK 839.00k
Other ExpensesNOK 58.85m
Earnings-NOK 58.01m

Last Reported Earnings

Dec 31, 2025

Next Earnings Date

Aug 28, 2026

Earnings per share (EPS)-0.16
Gross Margin100.00%
Net Profit Margin-6,914.42%
Debt/Equity Ratio0%

How did 8NN perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/07/23 23:42
End of Day Share Price 2026/07/23 00:00
Earnings2025/12/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Thor Medical ASA is covered by 1 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Geir HolomDNB Carnegie